This investigation or therapeutic intervention is of limited gain for patients and may be done g., PARP inhibitor) for a consequence of knowledge on the use of PARP inhibitors in BRCA1/2 mutation carriers with Highly developed breast cancer (LoE 1b/GR B/In the past+) [six] (see also the chapter on https://chesterk319gnu5.wikipowell.com/user